Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

A booster dose is immunogenic and will be needed for older adults who have completed two doses vaccination with CoronaVac: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Minjie Li, Juan Yang, Lin Wang, Qianhui Wu, Zhiwei Wu, Wen Zheng, Lei Wang, Wanying Lu, Xiaowei Deng, Cheng Peng, Bihua Han, Yuliang Zhao, Hongjie Yu, Weidong Yin
doi: https://doi.org/10.1101/2021.08.03.21261544
Minjie Li
1Hebei Center for Disease Control and Prevention, Shijiazhuang, China
MSc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juan Yang
2School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lin Wang
3R&D Department, Sinovac Life Sciences Co., Ltd., Beijing, China
MSc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qianhui Wu
2School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China
MPH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhiwei Wu
1Hebei Center for Disease Control and Prevention, Shijiazhuang, China
MSc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wen Zheng
2School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China
BSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lei Wang
4Department of Clinical Research, Sinovac Biotech Co., Ltd., Beijing, China
MSc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wanying Lu
2School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China
BSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaowei Deng
2School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China
MSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cheng Peng
2School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China
BSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bihua Han
1Hebei Center for Disease Control and Prevention, Shijiazhuang, China
MSc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuliang Zhao
1Hebei Center for Disease Control and Prevention, Shijiazhuang, China
MSc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Yuliang_zh1@163.com yhj@fudan.edu.cn yinwd@sinovac.com
Hongjie Yu
2School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China
5Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China
6Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China
M.D. Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Yuliang_zh1@163.com yhj@fudan.edu.cn yinwd@sinovac.com
Weidong Yin
7General Manager’s Office. Sinovac Biotech Co., Ltd., Beijing, China
MBA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Yuliang_zh1@163.com yhj@fudan.edu.cn yinwd@sinovac.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Importance Whether herd immunity through mass vaccination is sufficient to curb SARS-CoV-2 transmission requires an understanding of the duration of vaccine-induced immunity, and the necessity and timing of booster doses. Objective: To evaluate immune persistence of two priming doses of CoronaVac, and immunogenicity and safety of a third dose in healthy adults ≥60 years. Design, setting, and participants: We conducted a vaccine booster study built on a single-center, randomized, double-blind phase 1/2 trial of the two-dose schedule of CoronaVac among healthy adults≥60 years in Hebei, China. We examined neutralizing antibody titres six months or more after the second dose in all participants. We provided a third dose to 303 participants recruited in phase 2 trial to assess their immune responses.

Interventions Two formulations (3 μg, and 6 μg) were used in phase 1 trial, and an additional formulation of 1.5 μg was used in phase 2 trial. All participants were given two doses 28 days apart and followed up 6 months after the second dose. Participants in phase 2 received a third dose 8 months after the second dose.

Main outcomes and measures Geometric mean titres (GMT) of neutralizing antibodies to live SARS-CoV-2 and adverse events were assessed at multiple time points following vaccination.

Results Neutralizing antibody titres dropped below the seropositive cutoff of 8 at 6 months after the primary vaccination in all vaccine groups in the phase 1/2 trial. A third dose given 8 months or more after the second dose significantly increased neutralizing antibody levels. In the 3 μg group (the licensed formulation), GMT increased to 305 [95%CI 215.3-432.0] on day 7 following the third dose, an approximately 7-fold increase compared with the GMT 28 days after the second dose. All solicited adverse reactions reported within 28 days after a booster dose were of grade 1 or 2 severity.

Conclusion and relevance Neutralizing antibody titres declined substantially six months after two doses of CoronaVac among older adults. A booster dose rapidly induces robust immune responses. This evidence could help policymakers determine the necessity and the timing of a booster dose for older adults.

Trial registration ClinicalTrials.gov (NCT04383574).

Competing Interest Statement

H.Y. has received research funding from Sanofi Pasteur, GlaxoSmithKline, Yichang HEC Changjiang Pharmaceutical Company, and Shanghai Roche Pharmaceutical Company. None of those research funding is related to development of COVID-19 vaccines. L.W. and Y.W. were the employees of Sinovac Biotech Ltd., L.W. was an employee of Sinovac Life Sciences Co., Ltd. All other authors report no competing interests.

Clinical Trial

ClinicalTrials.gov (NCT04383574)

Funding Statement

The study was supported by grants from National Key Research and Development Program (2020YFC0849600), Beijing Science and Technology Program (Z201100005420023), and National Science Fund for Distinguished Young Scholars (81525023).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Written informed consent was obtained from each participant before the third dose in the second part of the study. The clinical trial protocol and informed consent form were approved by the Ethics Committee of Hebei CDC (IRB2020-006).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All the data referred to in the manuscript will be provided with reasonable request after the trial is completed.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted August 08, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
A booster dose is immunogenic and will be needed for older adults who have completed two doses vaccination with CoronaVac: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
A booster dose is immunogenic and will be needed for older adults who have completed two doses vaccination with CoronaVac: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
Minjie Li, Juan Yang, Lin Wang, Qianhui Wu, Zhiwei Wu, Wen Zheng, Lei Wang, Wanying Lu, Xiaowei Deng, Cheng Peng, Bihua Han, Yuliang Zhao, Hongjie Yu, Weidong Yin
medRxiv 2021.08.03.21261544; doi: https://doi.org/10.1101/2021.08.03.21261544
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
A booster dose is immunogenic and will be needed for older adults who have completed two doses vaccination with CoronaVac: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
Minjie Li, Juan Yang, Lin Wang, Qianhui Wu, Zhiwei Wu, Wen Zheng, Lei Wang, Wanying Lu, Xiaowei Deng, Cheng Peng, Bihua Han, Yuliang Zhao, Hongjie Yu, Weidong Yin
medRxiv 2021.08.03.21261544; doi: https://doi.org/10.1101/2021.08.03.21261544

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (269)
  • Allergy and Immunology (549)
  • Anesthesia (134)
  • Cardiovascular Medicine (1747)
  • Dentistry and Oral Medicine (238)
  • Dermatology (172)
  • Emergency Medicine (310)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (653)
  • Epidemiology (10780)
  • Forensic Medicine (8)
  • Gastroenterology (584)
  • Genetic and Genomic Medicine (2933)
  • Geriatric Medicine (286)
  • Health Economics (531)
  • Health Informatics (1918)
  • Health Policy (833)
  • Health Systems and Quality Improvement (743)
  • Hematology (290)
  • HIV/AIDS (627)
  • Infectious Diseases (except HIV/AIDS) (12496)
  • Intensive Care and Critical Care Medicine (684)
  • Medical Education (299)
  • Medical Ethics (86)
  • Nephrology (321)
  • Neurology (2780)
  • Nursing (150)
  • Nutrition (431)
  • Obstetrics and Gynecology (554)
  • Occupational and Environmental Health (597)
  • Oncology (1454)
  • Ophthalmology (440)
  • Orthopedics (172)
  • Otolaryngology (255)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (379)
  • Pediatrics (865)
  • Pharmacology and Therapeutics (362)
  • Primary Care Research (333)
  • Psychiatry and Clinical Psychology (2630)
  • Public and Global Health (5338)
  • Radiology and Imaging (1002)
  • Rehabilitation Medicine and Physical Therapy (594)
  • Respiratory Medicine (722)
  • Rheumatology (329)
  • Sexual and Reproductive Health (288)
  • Sports Medicine (278)
  • Surgery (327)
  • Toxicology (47)
  • Transplantation (149)
  • Urology (125)